Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab in prurigo nodularis (China)
CTR20200578Phase 3Completed
- Sponsor
- Sanofi
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of dupilumab in prurigo nodularis (PN), sponsored by Sanofi. Started Apr 2020; status: completed.
02
Drugs
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on CTR20200578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200578.